1.156SEK-7.52%Mkt Cap: 128.77M SEKP/E: —Last update: 2026-06-01
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal strom…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap128.77M SEK
Enterprise Value110.98M SEK
Revenue (TTM)9.83M SEK
Gross Profit1.63M SEK
Net Income (TTM)-39.35M SEK
Revenue/Share—
Last Price1.156 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.00
EV/Revenue11.29
P/S14.16
P/B2.75
EPS (TTM)-0.43
EPS (Forward)—
52W Range
0.630046% of range1.784
52W High1.784 SEK
52W Low0.6300 SEK
Profitability
Gross Margin16.38%
Oper. Margin-761.16%
EBITDA Margin0.00%
Profit Margin-395.19%
ROE-77.77%
ROA-61.57%
Growth
Revenue Growth-41.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-37.78M SEK
CapEx (TTM)82.92K SEK
FCF Margin—
FCF Yield—
Net Debt-26.03M SEK
Net Debt/EBITDA0.70
Balance Sheet
Debt/Equity—
Current Ratio5.16
Quick Ratio3.92
Book Value/Sh0.4540 SEK
Cash/Share0.2340 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.500 SEK
Target Range3.500 SEK – 3.500 SEK
# Analysts1
Ownership
Shares Out.111.39M
Float86.02M
Insiders30.93%
Institutions6.56%
Technical
SMA 501.218 (-5.1%)
SMA 2001.077 (+7.4%)
Beta0.65
S&P 52W Chg27.70%
Avg Vol (30d)736.40K
Avg Vol (10d)322.27K
Technical Indicators
RSI (14)54.6
MACD0.0070
MACD Signal-0.0116
MACD Hist.+0.0187
BB Upper1.326 SEK
BB Middle1.171 SEK
BB Lower1.016 SEK
BB Width26.50%
ATR (14)0.1116 SEK
Vol Ratio (20d)1.27x